Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
368 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cystic Fibrosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H2 2015', provides an overview of the Cystic Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Cystic Fibrosis Overview 12 Therapeutics Development 13 Pipeline Products for Cystic Fibrosis - Overview 13 Pipeline Products for Cystic Fibrosis - Comparative Analysis 14 Cystic Fibrosis - Therapeutics under Development by Companies 15 Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 21 Cystic Fibrosis - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Cystic Fibrosis - Products under Development by Companies 26 Cystic Fibrosis - Products under Investigation by Universities/Institutes 33 Cystic Fibrosis - Companies Involved in Therapeutics Development 34 Actelion Ltd 34 Akari Therapeutics, Plc 35 Alaxia SAS 36 AlgiPharma AS 37 AmpliPhi Biosciences Corporation 38 Arcturus Therapeutics, Inc 39 Aridis Pharmaceuticals LLC 40 Bayer AG 41 Boehringer Ingelheim GmbH 42 Carolus Therapeutics, Inc. 43 Celtaxsys, Inc. 44 Chiesi Farmaceutici SpA 45 Cilian AG 46 Concert Pharmaceuticals, Inc. 47 Corbus pharmaceuticals, Inc. 48 Cyclacel Pharmaceuticals, Inc. 49 DiscoveryBiomed, Inc. 50 Errant Gene Therapeutics, LLC 51 Galapagos NV 52 GlaxoSmithKline Plc 53 Grifols, S.A. 54 Grupo Praxis Pharmaceutical SA 55 Horizon Pharma Plc 56 Insmed Incorporated 57 Invion Limited 58 JHL Biotech, Inc. 59 Kamada Ltd. 60 La Jolla Pharmaceutical Company 61 Lamellar Biomedical Ltd 62 Laurent Pharmaceuticals Inc. 63 Merck & Co., Inc. 64 Microbion Corporation 65 Mucokinetica Ltd. 66 NanoBio Corporation 67 Nivalis Therapeutics, Inc. 68 Nostrum Pharmaceuticals, LLC 69 Novabiotics Limited 70 Novartis AG 71 OSE Pharma SA 72 Parion Sciences, Inc. 73 Pfizer Inc. 74 Pharmaxis Limited 75 PhaseBio Pharmaceuticals, Inc. 76 Polyphor Ltd. 77 Progenra, Inc. 78 ProQR Therapeutics N.V. 79 Protalix BioTherapeutics, Inc. 80 Proteostasis Therapeutics, Inc. 81 PTC Therapeutics, Inc. 82 Pulmatrix, Inc. 83 ReveraGen BioPharma, Inc. 84 Savara Inc. 85 Serendex Pharmaceuticals A/S 86 Shionogi & Co., Ltd. 87 Shire Plc 88 Synovo GmbH 89 TGV-Laboratories 90 The International Biotechnology Center (IBC) Generium 91 Verona Pharma Plc 92 Vertex Pharmaceuticals Incorporated 93 Xenetic Biosciences plc 94 Zambon Company S.p.A. 95 Cystic Fibrosis - Therapeutics Assessment 96 Assessment by Monotherapy Products 96 Assessment by Combination Products 97 Assessment by Target 98 Assessment by Mechanism of Action 102 Assessment by Route of Administration 105 Assessment by Molecule Type 107 Drug Profiles 109 (ammonium chloride + citric acid + sodium citrate) - Drug Profile 109 (fosfomycin + tobramycin) - Drug Profile 110 (lumacaftor + ivacaftor) - Drug Profile 111 (tezacaftor + ivacaftor) - Drug Profile 114 ABPA-01 - Drug Profile 116 acebilustat - Drug Profile 118 Aerucin - Drug Profile 120 alpha-1 proteinase inhibitor (human) second generation - Drug Profile 121 ALX-009 - Drug Profile 124 amikacin sulphate - Drug Profile 126 amlexanox - Drug Profile 131 Anti-Pseudomonas IgY - Drug Profile 132 Antimicrobial Drug for Cystic Fibrosis - Drug Profile 134 AT-010 - Drug Profile 135 ataluren - Drug Profile 136 Biologics for Cystic Fibrosis Lung Infections - Drug Profile 140 budesonide - Drug Profile 141 Calcaftor - Drug Profile 142 CFX-1 - Drug Profile 143 CSY-0073 - Drug Profile 144 CT-2009 - Drug Profile 145 CTP-656 - Drug Profile 146 cysteamine IR - Drug Profile 147 dapsone - Drug Profile 149 Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis - Drug Profile 150 doripenem - Drug Profile 151 dornase alfa biosimilar - Drug Profile 153 dornase alfa biosimilar - Drug Profile 154 Drug for Cystic Fibrosis - Drug Profile 155 FDL-169 - Drug Profile 156 fenretinide - Drug Profile 157 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 158 Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile 160 Gene Therapy to Activate CFTR Gene for Cystic Fibrosis - Drug Profile 161 GLPG-1837 - Drug Profile 162 GLPG-2222 - Drug Profile 164 GLPG-2665 - Drug Profile 165 glycerol phenylbutyrate - Drug Profile 166 GSK-2225745 - Drug Profile 169 JBT-101 - Drug Profile 170 kenpaullone - Drug Profile 172 levofloxacin - Drug Profile 173 LJPC-30Sa - Drug Profile 174 LJPC-30Sb - Drug Profile 175 LMS-611 - Drug Profile 176 LUNAR-CF - Drug Profile 177 mannitol - Drug Profile 178 MG-277 - Drug Profile 181 miglustat - Drug Profile 182 MKA-104 - Drug Profile 184 molgramostim - Drug Profile 185 Mul-1867 - Drug Profile 189 N-91115 - Drug Profile 190 N-91138 - Drug Profile 191 N-91169 - Drug Profile 192 nadolol - Drug Profile 193 NB-401 - Drug Profile 195 nitric oxide - Drug Profile 196 nitric oxide - Drug Profile 198 NVPQBE-170 - Drug Profile 199 Oligomer G for Cystic Fibrosis - Drug Profile 200 ORP-100 - Drug Profile 202 P-1055 - Drug Profile 203 Panaecin - Drug Profile 204 PB-01 - Drug Profile 206 PB-1046 - Drug Profile 208 PB-1120 - Drug Profile 210 Peptide to Block ENaC for Cystic Fibrosis and Hypertension - Drug Profile 211 POL-6014 - Drug Profile 212 PRX-110 - Drug Profile 214 Pseudomonas aeruginosa vaccine - Drug Profile 215 PTI-130 - Drug Profile 216 PTI-428 - Drug Profile 217 PTIC-1811 - Drug Profile 218 PTIP-271 - Drug Profile 219 PulmoXen - Drug Profile 220 PUR-1900 - Drug Profile 221 PXS-4728A - Drug Profile 222 QBW-251 - Drug Profile 223 QBW-276 - Drug Profile 224 QR-010 - Drug Profile 225 QR-X4 - Drug Profile 226 Recombinant A1PI - Drug Profile 227 Recombinant Enzyme to Replace Acid Ceramidase for Farber Disease and Cystic Fibrosis - Drug Profile 229 Recombinant Enzyme to Target DNA for Cystic Fibrosis - Drug Profile 230 Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile 231 riociguat - Drug Profile 232 RPL-554 - Drug Profile 234 S-1226 - Drug Profile 237 S-1229 - Drug Profile 239 S-18 - Drug Profile 240 seliciclib - Drug Profile 241 SHP-636 - Drug Profile 243 Small Molecule for Cystic Fibrosis - Drug Profile 244 Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile 245 Small Molecule to Activate CFTR for Cystic Fibrosis - Drug Profile 246 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 247 Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile 248 Small Molecules for Bacterial Infections - Drug Profile 249 Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile 250 Small Molecules for Cystic Fibrosis - Drug Profile 251 Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile 252 Small Molecules to Activate CFTR Protein for Cystic Fibrosis - Drug Profile 253 Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis - Drug Profile 254 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 255 Small Molecules to Inhibit Sodium Channels for Cystic Fibrosis - Drug Profile 256 Small Molecules to Inhibit USP8 for Cystic Fibrosis - Drug Profile 257 solithromycin - Drug Profile 258 SP-14 - Drug Profile 261 SP-9 - Drug Profile 262 Stem Cell Therapy for Cystic Fibrosis - Drug Profile 263 SYGN-113 - Drug Profile 264 SYGN-303 - Drug Profile 265 tritoqualine - Drug Profile 266 vancomycin hydrochloride - Drug Profile 267 Verolone - Drug Profile 269 VX-152 - Drug Profile 271 VX-371 - Drug Profile 272 VX-440 - Drug Profile 273 ZP-046 - Drug Profile 274 Cystic Fibrosis - Recent Pipeline Updates 275 Cystic Fibrosis - Dormant Projects 343 Cystic Fibrosis - Discontinued Products 351 Cystic Fibrosis - Product Development Milestones 352 Featured News & Press Releases 352 Appendix 359 Methodology 359 Coverage 359 Secondary Research 359 Primary Research 359 Expert Panel Validation 359 Contact Us 359 Disclaimer 360
List of Tables
Number of Products under Development for Cystic Fibrosis, H2 2015 21 Number of Products under Development for Cystic Fibrosis - Comparative Analysis, H2 2015 22 Number of Products under Development by Companies, H2 2015 24 Number of Products under Development by Companies, H2 2015 (Contd..1) 25 Number of Products under Development by Companies, H2 2015 (Contd..2) 26 Number of Products under Development by Companies, H2 2015 (Contd..3) 27 Number of Products under Development by Companies, H2 2015 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H2 2015 29 Comparative Analysis by Late Stage Development, H2 2015 30 Comparative Analysis by Clinical Stage Development, H2 2015 31 Comparative Analysis by Early Stage Development, H2 2015 32 Comparative Analysis by Unknown Stage Development, H2 2015 33 Products under Development by Companies, H2 2015 34 Products under Development by Companies, H2 2015 (Contd..1) 35 Products under Development by Companies, H2 2015 (Contd..2) 36 Products under Development by Companies, H2 2015 (Contd..3) 37 Products under Development by Companies, H2 2015 (Contd..4) 38 Products under Development by Companies, H2 2015 (Contd..5) 39 Products under Development by Companies, H2 2015 (Contd..6) 40 Products under Investigation by Universities/Institutes, H2 2015 41 Cystic Fibrosis - Pipeline by Actelion Ltd, H2 2015 42 Cystic Fibrosis - Pipeline by Akari Therapeutics, Plc, H2 2015 43 Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2015 44 Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2015 45 Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corporation, H2 2015 46 Cystic Fibrosis - Pipeline by Arcturus Therapeutics, Inc, H2 2015 47 Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H2 2015 48 Cystic Fibrosis - Pipeline by Bayer AG, H2 2015 49 Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2015 50 Cystic Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2015 51 Cystic Fibrosis - Pipeline by Celtaxsys, Inc., H2 2015 52 Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2015 53 Cystic Fibrosis - Pipeline by Cilian AG, H2 2015 54 Cystic Fibrosis - Pipeline by Concert Pharmaceuticals, Inc., H2 2015 55 Cystic Fibrosis - Pipeline by Corbus pharmaceuticals, Inc., H2 2015 56 Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 57 Cystic Fibrosis - Pipeline by DiscoveryBiomed, Inc., H2 2015 58 Cystic Fibrosis - Pipeline by Errant Gene Therapeutics, LLC, H2 2015 59 Cystic Fibrosis - Pipeline by Galapagos NV, H2 2015 60 Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2015 61 Cystic Fibrosis - Pipeline by Grifols, S.A., H2 2015 62 Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2015 63 Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2015 64 Cystic Fibrosis - Pipeline by Insmed Incorporated, H2 2015 65 Cystic Fibrosis - Pipeline by Invion Limited, H2 2015 66 Cystic Fibrosis - Pipeline by JHL Biotech, Inc., H2 2015 67 Cystic Fibrosis - Pipeline by Kamada Ltd., H2 2015 68 Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H2 2015 69 Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2015 70 Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc., H2 2015 71 Cystic Fibrosis - Pipeline by Merck & Co., Inc., H2 2015 72 Cystic Fibrosis - Pipeline by Microbion Corporation, H2 2015 73 Cystic Fibrosis - Pipeline by Mucokinetica Ltd., H2 2015 74 Cystic Fibrosis - Pipeline by NanoBio Corporation, H2 2015 75 Cystic Fibrosis - Pipeline by Nivalis Therapeutics, Inc., H2 2015 76 Cystic Fibrosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2015 77 Cystic Fibrosis - Pipeline by Novabiotics Limited, H2 2015 78 Cystic Fibrosis - Pipeline by Novartis AG, H2 2015 79 Cystic Fibrosis - Pipeline by OSE Pharma SA, H2 2015 80 Cystic Fibrosis - Pipeline by Parion Sciences, Inc., H2 2015 81 Cystic Fibrosis - Pipeline by Pfizer Inc., H2 2015 82 Cystic Fibrosis - Pipeline by Pharmaxis Limited, H2 2015 83 Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015 84 Cystic Fibrosis - Pipeline by Polyphor Ltd., H2 2015 85 Cystic Fibrosis - Pipeline by Progenra, Inc., H2 2015 86 Cystic Fibrosis - Pipeline by ProQR Therapeutics N.V., H2 2015 87 Cystic Fibrosis - Pipeline by Protalix BioTherapeutics, Inc., H2 2015 88 Cystic Fibrosis - Pipeline by Proteostasis Therapeutics, Inc., H2 2015 89 Cystic Fibrosis - Pipeline by PTC Therapeutics, Inc., H2 2015 90 Cystic Fibrosis - Pipeline by Pulmatrix, Inc., H2 2015 91 Cystic Fibrosis - Pipeline by ReveraGen BioPharma, Inc., H2 2015 92 Cystic Fibrosis - Pipeline by Savara Inc., H2 2015 93 Cystic Fibrosis - Pipeline by Serendex Pharmaceuticals A/S, H2 2015 94 Cystic Fibrosis - Pipeline by Shionogi & Co., Ltd., H2 2015 95 Cystic Fibrosis - Pipeline by Shire Plc, H2 2015 96 Cystic Fibrosis - Pipeline by Synovo GmbH, H2 2015 97 Cystic Fibrosis - Pipeline by TGV-Laboratories, H2 2015 98 Cystic Fibrosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 99 Cystic Fibrosis - Pipeline by Verona Pharma Plc, H2 2015 100 Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 101 Cystic Fibrosis - Pipeline by Xenetic Biosciences plc, H2 2015 102 Cystic Fibrosis - Pipeline by Zambon Company S.p.A., H2 2015 103 Assessment by Monotherapy Products, H2 2015 104 Assessment by Combination Products, H2 2015 105 Number of Products by Stage and Target, H2 2015 107 Number of Products by Stage and Mechanism of Action, H2 2015 111 Number of Products by Stage and Route of Administration, H2 2015 114 Number of Products by Stage and Molecule Type, H2 2015 116 Cystic Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015 283 Cystic Fibrosis - Dormant Projects, H2 2015 351 Cystic Fibrosis - Dormant Projects (Contd..1), H2 2015 352 Cystic Fibrosis - Dormant Projects (Contd..2), H2 2015 353 Cystic Fibrosis - Dormant Projects (Contd..3), H2 2015 354 Cystic Fibrosis - Dormant Projects (Contd..4), H2 2015 355 Cystic Fibrosis - Dormant Projects (Contd..5), H2 2015 356 Cystic Fibrosis - Dormant Projects (Contd..6), H2 2015 357 Cystic Fibrosis - Dormant Projects (Contd..7), H2 2015 358 Cystic Fibrosis - Discontinued Products, H2 2015 359
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
